agenT-797 — Interim data
2026
2026: Early data from our randomized Phase 2 trial in severe pulmonary inflammatory diseaseSource filing
INKT biotech catalysts & pipeline
MINK THERAPEUTICS INC · Data as of 2026-09-08
Upcoming catalysts
agenT-797 — Topline data
H2 2026
The study, which initiated in Lviv, Ukraine, in partnership with First Lviv Territorial Medical Union and UNBROKEN Ukraine, is designed to evaluate clinically meaningful ICU endpoints including survival, ventilator-free days, and secondary infections, with U.S. sites enrolling in parallel and preliminary data expected in the second half of 2026.Source filing
agenT-797 — Initial data
by year end
• ARDS / hypoxemic pneumonia Phase 2 trial initiation 1H 2026; early data by year end; market opportunity of ~200,000–300,000 patients annually in US/EUSource filing
agenT-797 — Topline data
early 2027
Additional data are expected in early 2027.Source filing